C-reactive protein in aortic valve disease

Cardiovascular Ultrasound

Volumn 4, Issue , 2006, Pages

  Sanchez, Pedro L ^a   Mazzone, Anna Maria ^b  

^a HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

^b G PASQUINUCCI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LIPOPROTEIN; STATIN; BIOLOGICAL MARKER;

AORTA ATHEROSCLEROSIS; AORTA STENOSIS; AORTA VALVE DISEASE; BLOOD VESSEL CALCIFICATION; CARDIOVASCULAR RISK; CHRONIC INFLAMMATION; CONTROLLED STUDY; DEGENERATIVE DISEASE; DISEASE COURSE; HUMAN; MAJOR CLINICAL STUDY; REVIEW; ANIMAL; AORTA VALVE STENOSIS; BLOOD; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); METHODOLOGY; RETRACTED ARTICLE; RISK ASSESSMENT; RISK FACTOR;

ANIMALS; AORTIC VALVE STENOSIS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CLINICAL TRIALS AS TOPIC; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; RISK ASSESSMENT; RISK FACTORS;

EID: 39049191534     PISSN: 14767120     EISSN: 14767120     Source Type: Journal    
DOI: 10.1186/1476-7120-4-37     Document Type: Review

References (30)

1. Mazzone A, Epistolato MC, De Caterina R, Storti S, Vittorini S, Sbrana S, Gianetti J, Bevilacqua S, Glauber M, Biagini A, Tanganelli P: Neoangiogenesis, T-lymphocyte infiltration, and heat shock protein-60 are biological hallmarks of an immunomediated inflammatory process in end-stage calcified aortic valve stenosis. J Am Coll Cardiol 2004, 43:1670-6.
2. Rajamannan NM, Gersh B, Bonow RO: Calcific aortic stenosis: from bench to the bedside - emerging clinical and cellular concepts. Heart 2003, 89:801-5.
3. Freeman RV, Otto CM: Spectrum of calcific aortic valve disease: pathogenesis, disease progression, and treatment strategies. Circulation 2005, 111:3316-26.
4. O'Brien KD, Reichenbackh DD, Marcovina SM, et al.: Apolipoprotein B, (a), and E accumulate in the morphologically early lesion of degenerative valvular aortic stenosis. Arterioscler Thromb 1996, 16:523-532.
5. Myers GL, Rifai N, Tracy RP, Roberts WL, Alexander RW, Biasucci LM, Catravas JD, Cole TG, Cooper GR, Khan BV, Kimberly MM, Stein EA, Taubert KA, Warnick GR, Waymack PP, CDC; AHA: CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: report from the laboratory science discussion group. Circulation 2004, 110:e545-9.
6. Galante A, Pietroiusti A, Vellini M, Piccolo P, Possati G, De Bonis M, Grillo RL, Fontana C, Favalli C: C-reactive protein is increased in patients with degenerative aortic valvular stenosis. J Am Coll Cardiol 2001, 38:1078-82.
7. Gunduz H, Akdemir R, Binak E, Tamer A, Keser N, Uyan C: Can serum lipid and CRP levels predict the "severity" of aortic valve stenosis? Acta Cardiol 2003, 58:321-6.
8. Sanchez PL, Santos JL, Kaski JC, Cruz I, Arribas A, Villacorta E, Cascon M, Palacios I, Martín-Luengo C: Am J Cardiol in press.
9. Gerber IL, Stewart RA, Hammett CJ, Legget ME, Oxenham H, West TM, French JK, White HD: Effect of aortic valve replacement on c-reactive protein in nonrheumatic aortic stenosis. Am J Cardiol 2003, 92:1129-32.
10. Warrier B, Mallipeddi R, Karla PK, Lee CH: The functional role of C-reactive protein in aortic wall calcification. Cardiology 2005, 104:57-64.
11. Kajbaf S, Veinot JP, Ha A, Zimmerman D: Comparison of surgically removed cardiac valves of patients with ESRD with those of the general population. Am J Kidney Dis 2005, 46:86-93.
12. Movilli E, Feliciani A, Camerini C, Brunori G, Zubani R, Scolari F, Parrinello G, Cancarini GC: A high calcium-phosphate product is associated with high C-reactive protein concentrations in hemodialysis patients. Nephron Clin Pract 2005, 101:c161-7.
13. Torun D, Sezer S, Baltali M, Adam FU, Erdem A, Ozdemir FN, Haberal M: Association of cardiac valve calcification and inflammation in patients on hemodialysis. Ren Fail 2005, 27:221-6.
14. Skowasch D, Schrempf S, Preusse CJ, Likungu JA, Welz A, Luderitz B, Bauriedel G: Tissue-resident C-reactive protein within degenerative aortic valves: correlation with serum CRP levels and modification by statins. Heart in press. 2005 Sep 13
15. Lagrand WK, Visser CA, Hermens WT, Niessen HW, Verheugt FW, Wolbink GJ, Hack CE: C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon? Circulation 1999, 100:96-102.
16. Venugopal SK, Devaraj S, Yuhanna I, Shaul P, Jialal I: Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation 2002, 106:1439-1441.
17. Venugopal SK, Devaraj S, Jialal I: C-reactive protein decreases prostacyclin release from human aortic endothelial cells. Circulation 2003, 108:1676-1678.
18. Palta S, Pai AM, Gill KS, Pai RG: New insights into the progression of aortic stenosis: implications for secondary prevention. Circulation 2000, 101:2497-2502.
19. Otto CM, Burwash IG, Legget ME, Munt BI, Fujioka M, Healy NL, Kraft CD, Miyake-Hull CY, Schwaegler RG: A prospective study of asymptomatic valvular aortic stenosis: Clinical, echocardiographic, and exercise predictors of outcome. Circulation 1997, 95:2262-2270.
20. Chandra HR, Goldstein JA, Choudhary N, O'Neill CS, George PB, Gangasani SR, Cronin L, Marcovitz PA, Hauser AM, O'Neill WW: Adverse outcome in aortic sclerosis is associated with coronary artery disease and inflammation. J Am Coll Cardiol 2004, 43:169-75.
21. Rajamannan NM, Subramaniam M, Springett M, Sebo TC, Niekrasz M, McConnell JP, Singh RJ, Stone NJ, Bonow RO, Spelsberg TC: Atorvastatin inhibits hypercholesterolemia-induced cellular proliferation and bone matrix production in the rabbit aortic valve. Circulation 2002, 105:2660-5.
22. Rajamannan NM, Subramaniam M, Stock SR, Stone NJ, Springett M, Ignatiev KI, McConnell JP, Singh RJ, Bonow RO, Spelsberg TC: Atorvastatin inhibits calcification and enhances nitric oxide synthase production in the hypercholesterolaemic aortic valve. Heart 2005, 91:806-10.
23. Rajamannan NM, Subramaniam M, Caira F, Stock SR, Spelsberg TC: Atorvastatin inhibits hypercholesterolemia-induced calcification in the aortic valves via the Lrp5 receptor pathway. Circulation 2005, 112:I229-34.
24. Aronow WS, Ahn C, Kronzon I, Goldman ME: Association of coronary risk factors and use of statins with progression of mild valvular aortic stenosis in older persons. Am J Cardiol 2001, 88:693-695.
25. Novaro GM, Tiong IY, Pearce GL, Lauer MS, Sprecher DL, Griffin BP: Effect of hydroxymethylglutaryl coenzyme A reductase inhibitors on the progression of calcific aortic stenosis. Circulation 2001, 104:2205-2209.
26. Shavelle DM, Takasu J, Budoff MJ, Mao S, Zhao XQ, O'Brien KD: HMG CoA reductase inhibitor (statin) and aortic valve calcium. Lancet 2002, 359:1125-6.
27. Bellamy MF, Pellikka PA, Klarich KW, Tajik AJ, Enriquez-Sarano M: Association of cholesterol levels, hydroxymethylglutaryl conezyme-A reductase treatment, and progression of aortic stenosis in the community. J Am Coll Cardiol 2002, 40:1723-30.
28. Rosenhek R, Rader F, Loho N, Gabriel H, Heger M, Klaar U, Schemper M, Binder T, Maurer G, Baumgartner H: Statins but not angiotensinconverting enzyme inhibitors delay progression of aortic stenosis. Circulation 2004, 110:1291-5.
29. Cowell SJ, Newby DE, Prescott RJ, Bloomfield P, Reid J, Northridge DB, Boon NA, Scottish Aortic Stenosis and Lipid Lowering Trial, Impact on Regression (SALTIRE) Investigators: A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med 2005, 352:2389-97.
30. Rosenhek R: Statins for aortic stenosis. N Engl J Med 2005, 352:2441-3.